What changed: Erdheim-Chester disease
Every dated change on the records linked to Erdheim-Chester disease, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2022 · 1
2020 · 5
- 2020GuidelineErdheim-Chester diseaseGuideline Consensus recommendations for Erdheim-Chester disease (Blood 2020): Asymptomatic bone-limited disease
Observation with periodic PET and organ screening.
- 2020GuidelineErdheim-Chester diseaseGuideline Consensus recommendations for Erdheim-Chester disease (Blood 2020): BRAF V600E-mutant symptomatic disease
Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
- 2020GuidelineErdheim-Chester diseaseGuideline Consensus recommendations for Erdheim-Chester disease (Blood 2020): BRAF wild-type symptomatic disease
Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
- 2020GuidelineErdheim-Chester diseaseGuideline Consensus recommendations for Erdheim-Chester disease (Blood 2020): Diagnosis
Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.
- 2020GuidelineErdheim-Chester diseaseGuideline Consensus recommendations for Erdheim-Chester disease (Blood 2020): Second-choice or intolerant
Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.